Management of type 2 diabetes: A handbook for general practice

Microvascular complications: Diabetes-related eye disease

Download chapter

Last revised: 17 Sep 2020

  1. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2018;42:S1–325.
  2. National Health and Medical Research Council. Guidelines for the management of diabetic retinopathy. Canberra: NHMRC, 2008.
  3. Royal Australian and New Zealand College of Ophthalmologists. RANZCO screening and referral pathway for diabetic retinopathy. Surry Hills, NSW: RANZCO, 2019.
  4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2019;42:S1–194.
  5. Smith-Morris C, Bresnick GH, Cuadros J, Bouskill KE, Pedersen ER. Diabetic retinopathy and the cascade into vision loss. Med Anthropol 2020;39(2):109–22.
  6. Khoo K, Man REK, Rees G, Gupta P, Lamoureux EL, Fenwick EK. The relationship between diabetic retinopathy and psychosocial functioning: A systematic review. Qual Life Res 2019;28(8):2017–39.
  7. Dirani M. Out of sight: A report into diabetic eye disease in Australia. Melbourne: Baker IDI Heart and Diabetes Institute and the Centre for Eye Research Australia, 2013.
  8. Xie J, Ikram MK, Cotch MF, et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: A systemic review and meta-analysis. JAMA Ophthalmol 2017;135(6):586–93.
  9. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47(6):1703–20.
  10. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837–53.
  11. Chew EW, Davis ME, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye study. Ophthalmology 2014;121(12):2443–51.
  12. Liu Y, Li J, Ma J, Tong N. The threshold of the severity of diabetic retinopathy below which intensive glycemic control is beneficial in diabetic patients: Estimation using data from large randomized clinical trials. J Diabetes Res 2020. doi: 10.1155/2020/8765139.
  13. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703.
  14. Lipidil [fenofibrate] product information. Botany, NSW: Abbott Australasia, 2014 [Accessed 17 April 2020].
  15. Sharma N, Ooi J-L, Ong J, Newman, D. The use of fenofibrate in the management of patients with diabetic retinopathy: An evidence-based review. Aust Fam Physician 2015;44(6):367–70. [fenofibrate] product information. Botany, NSW: Abbott Australasia, 2014 [Accessed 17 April 2020].
  16. National Health and Medical Research Council. Guidelines for the screening, prognosis, diagnosis, management and prevention of glaucoma. Canberra: NHMRC, 2010. [fenofibrate] product information. Botany, NSW: Abbott Australasia, 2014 [Accessed 17 April 2020].